Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) FCF Margin (2020 - 2025)

Rani Therapeutics Holdings has reported FCF Margin over the past 5 years, most recently at 21.08% for Q4 2025.

  • Quarterly results put FCF Margin at 21.08% for Q4 2025, up 86602.0% from a year ago — trailing twelve months through Dec 2025 was 1150.52% (up 232847.0% YoY), and the annual figure for FY2025 was 1150.52%, up 232847.0%.
  • FCF Margin for Q4 2025 was 21.08% at Rani Therapeutics Holdings, up from 4737.79% in the prior quarter.
  • Over the last five years, FCF Margin for RANI hit a ceiling of 1164.67% in Q3 2023 and a floor of 4737.79% in Q1 2025.
  • Median FCF Margin over the past 4 years was 21.08% (2025), compared with a mean of 252.21%.
  • Biggest five-year swings in FCF Margin: tumbled -182064bps in 2024 and later skyrocketed 86602bps in 2025.
  • Rani Therapeutics Holdings' FCF Margin stood at 281.95% in 2021, then skyrocketed by 446bps to 975.69% in 2023, then plummeted by -187bps to 844.94% in 2024, then skyrocketed by 102bps to 21.08% in 2025.
  • The last three reported values for FCF Margin were 21.08% (Q4 2025), 4737.79% (Q1 2025), and 844.94% (Q4 2024) per Business Quant data.